Studies showed that LipiGesic M provides a safe, highly effective OTC solution to migraine pain and performs better than the prescription migraine medications.
LipiGesic M completed the original double-blind, placebo-controlled clinical trial in 2010 and was found to provide relief to around 64% of patients.
PuraMed BioScience CEO Russ Mitchell said that with at least 39 million Americans affected by migraines and LipiGesic M currently retailing for around $19.95 per box, the revenue potential for the product will be substantial.
"Since the performance of LipiGesic M, is more aptly compared to prescription formulations, rather than over-the-counter products, we believe that people currently paying $40 or more for one prescription migraine treatment will turn to LipiGesic M as a highly effective, money-saving alternative that costs approximately $5 per treatment," Mitchell added.
The migraine treatment product is currently available in national retail drugstore chains, such as Walgreens and CVS/pharmacy stores with expansion plans to additional retail chains in the US, as well as International distribution.